Taking advantage of the discoveries and therapeutics designed to attenuate tau dysfunction in AD (101), as a significant number of preclinical studies and clinical trials have already been initiated, may indeed prove to be useful in HD as well. This evidence concerns the gene MAPT and Huntington disease.